| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Immuneering Corporation$5.11
-0.25 (-4.66%)
C 54Pipeline Score Undervalued Pharma · Clinical
Market Cap
348.72 M
EPS
-1.17
P/E Ratio
-
Value Trade
8.67 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
10.65 M
Operating CF
-18.43 M
Total Assets
214.81 M
Total Liabilities
8.29 M
Equity
206.52 M
D/E Ratio
12,345
5.69 %
Week
-3.58 %
1 Month
2.67 %
3 Month
-22.45 %
6 Month
-72.36 %
5 Year
-72.36 %
All Time
Cash Data
Cash Position
198.64 M
Monthly Burn
6.14 M
Runway
30.7 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
827.75 K
52 Week Range
1.56 - 10.08
% held by Insiders
13.67 %
% held by Institutions
47.37 %
Enterprise Value
195.75 M
Total Shares
64.66 M
Short %
26.87 %
Float Shares
55.93 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immuneering Corporation
129Total events
11Upcoming
27Tier-1 (high impact)
2021 – 2029Coverage
Upcoming catalysts 11
2026-H2
T2First Patient Dosed
First patient dosed in Phase 2 trial of atebimetinib + cemiplimab in NSCLC
2026-H1
T1Full Results
Report updated survival data from over 50 first-line pancreatic cancer patients
2026-H1
T2Timing Guidance
Expects to share updated survival data from atebimetinib + mGnP study in first-line pancreatic cancer in first half of 2026
2026-H1
T2Trial Initiation
Plans to begin dosing patients in Phase 3 study of atebimetinib + mGnP by mid-2026
Event history 118
Q3 2026
▲First Patient DosedAtebimetinibTrial
First patient dosed in Phase 2 trial of atebimetinib + Libtayo in NSCLC
RAS-mutant first-line non-small cell lung cancersource ↗
Jun 11, 2026
▲First Patient DosedAtebimetinibTrial
First patient dosed in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer
first-line metastatic pancreatic cancersource ↗
Jun 2026
◆Trial InitiationAtebimetinibTrial
Phase 3 trial of atebimetinib in first-line pancreatic cancer expected to begin dosing
first-line pancreatic cancersource ↗
Jun 2026
◆First Patient DosedAtebimetinibTrial
First patient dosed in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP
first-line metastatic pancreatic cancersource ↗
Jun 1, 2026
◆Oral PresentationAtebimetinibPresentation
Oral presentation of updated data from Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer at ASCO 2026
first-line pancreatic cancersource ↗
May 22, 2026
▲Topline ReadoutAtebimetinibClinical Data
17.3 months median overall survival reported in Phase 2a trial of atebimetinib plus mGnP
first-line metastatic pancreatic cancersource ↗
Apr 24, 2026
▲Full ResultsAtebimetinibClinical Data
Updated Phase 2a data: 17.3 months median OS, 8.3 months median PFS, 82% DCR, 36% ORR
first-line metastatic pancreatic ductal adenocarcinomasource ↗
Apr 20, 2026
◆Poster PresentationAtebimetinibPresentation
AACR 2026 poster presentation on atebimetinib's Deep Cyclic Inhibition constraining MAPK-axis alterations
RAS-mutant tumorssource ↗
Apr 13, 2026
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
▲First Patient DosedAtebimetinibTrial
Dose first patient in pivotal Phase 3 trial MAPKeeper 301
first-line pancreatic cancersource ↗
Drug Pipeline Intelligence
C54
Pipeline Score $1.3B
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored3.8x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 911)
Percentile RankImmuneering Corporation carries a moderate pipeline score (54/100), with $3.3B risk-adjusted pipeline value, led by IMM-1-104 Monotherapy in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMM-6-415 Small molecule | Advanced Solid Tumor (Phase 1) | Phase 1 | NCT06208124 | 5% | $1.6B | COMPLETED | 30 | - | - | Apr 30, 2025 | - | May 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
atebimetinib | first-line metastatic pancreatic cancer | Phase 2a | 2026-06-01 | median overall survival: 17.3 months; historical median: 8.5 months; weight stability: 84% Read More | Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO Read More | |
atebimetinib | first-line metastatic pancreatic cancer | Phase 2a | 2026-06-01 | median overall survival: 17.3 months; historical median: 8.5 months; weight stability: 84% Read More | Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO Read More | |
atebimetinib | first-line metastatic pancreatic cancer | Phase 2a | 2026-06-01 | median overall survival: 17.3 months; historical median: 8.5 months; weight stability: 84% Read More | Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMRXJune 2026 – OncLive
The article primarily consists of a privacy overview regarding cookie usage on a website. It discusses the necessity of cookies for user experience and the use of Google Analytics for collecting visitor data. There are no specific developments or news related to IMRX mentioned in the text.
Read more →IMRXImmuneering Appoints Andrew Gengos as Chief Financial Officer
Immuneering Corporation has appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos, previously CFO at Terns Pharmaceuticals, will oversee financial strategy and corporate development as the company progresses its lead oncology candidate, atebimetinib, currently in Phase 3 trials for pancreatic cancer. His extensive experience in biotech is expected to enhance Immuneering's growth.
Read more →IMRX▲ +5.1%on this newsshared move
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Corporation has announced that the first patient has been dosed in the MAPKeeper 301 pivotal Phase 3 trial, which studies the combination of atebimetinib and modified gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The trial aims to demonstrate the efficacy and safety of this new treatment regimen compared to standard therapy. Overall survival is the primary endpoint, with additional metrics being evaluated, and topline data is expected to be available in mid-2028.
Read more →IMRX▼ -8%on this newsshared move
June 2026 – OncLive
The article primarily discusses the use of cookies on a website to enhance user experience. It emphasizes the importance of enabling necessary cookies for saving user preferences and mentions the use of Google Analytics for collecting anonymous visitor data. Overall, the content focuses on privacy and website functionality.
Read more →IMRXJune 2026 – BioWorld
The article primarily discusses the use of cookies on the BioWorld website, emphasizing the importance of user experience and analytics. It highlights the necessity of enabling certain cookies to save user preferences and improve site functionality. However, there are no specific news events or updates related to IMRX mentioned.
Read more →IMRXResults from a phase 2a study of atebimetinib in combination with mGnP in first-line metastatic pancreatic cancer
The article discusses the phase 2a study results of atebimetinib in combination with mGnP for first-line treatment of metastatic pancreatic cancer. However, specific results or conclusions from the study are not provided in the text. The focus appears to be on the use of cookies and analytics on the website.
Read more →IMRXJune 2026 – Biotech TV
The article provides an overview of the website's privacy and cookie policy. It discusses the necessity of cookies for user experience and analytics. The content emphasizes the importance of enabling necessary cookies to save user preferences and improve website functionality.
Read more →IMRXJune 2026 – BioSpace
The article primarily discusses the privacy overview and cookie usage on the BioSpace website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. There are no specific news events or updates related to IMRX.
Read more →IMRXMay 2026 – BioCentury
The article primarily discusses the privacy overview and cookie usage on the website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for tracking visitor data. There are no specific news events or updates related to IMRX.
Read more →IMRXMay 2026 – BioWorld
The article provides an overview of the website's privacy policy, particularly focusing on cookie usage and analytics. It emphasizes the importance of enabling necessary cookies for optimal user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to enhance website functionality.
Read more →IMRX▼ -22.1%on this newsshared move
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Corporation presented promising data from its Phase 2a trial showing an impressive median overall survival of 17.3 months in 55 first-line pancreatic cancer patients treated with atebimetinib combined with chemotherapy. This outcome notably exceeds the historical median of 8.5 months reported in the standard of care chemotherapy. The trial exhibited only limited severe adverse events and a favorable tolerability profile, with a high percentage of participants maintaining or gaining weight. The ongoing recruitment for the Phase 3 MAPKeeper 301 trial aims to further evaluate atebimetinib's effectiveness in this patient population.
Read more →IMRXImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Corporation reported a 17.3-month median overall survival for first-line metastatic pancreatic cancer patients treated with atebimetinib plus chemotherapy in a Phase 2a trial. The trial included 55 patients, with a tolerability profile consistent with prior updates. The company plans to present detailed findings at the ASCO Annual Meeting on June 1, 2026, and is currently recruiting for a pivotal Phase 3 trial.
Read more →IMRXMay 2026 – BioSpace
The article primarily discusses the privacy overview and cookie usage on the BioSpace website. It highlights the necessity of enabling cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. There are no specific news events or updates related to IMRX.
Read more →IMRXImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be pres
Immuneering Corporation has reported positive financial results for Q1 2026, showcasing new survival data from its Phase 2a clinical trial of atebimetinib in first-line metastatic pancreatic cancer set to be presented at the upcoming ASCO Annual Meeting. The company's pivotal Phase 3 MAPKeeper 301 trial is actively recruiting patients, with expectations to dose the first participant by mid-2026. Amid an overall cash position of $198.6 million, which is projected to sustain operations until 2029, Immuneering's developments suggest strong potential in improving treatment outcomes for pancreatic cancer patients.
Read more →IMRXImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Corporation announced that new survival data from its Phase 2a clinical trial of atebimetinib combined with mGnP in first-line pancreatic cancer patients will be presented at the 2026 ASCO Annual Meeting. The presentation will include data from an expanded cohort of 55 patients, highlighting the treatment's potential to positively impact survival rates. Immuneering aims to showcase the efficacy of atebimetinib, which is designed to shrink tumors while preserving body mass and ensuring tolerability. This oral presentation marks a key moment for the company as it continues to develop innovative cancer treatments.
Read more →IMRXAtebimetinib’s Deep Cyclic Inhibition of MEK Constrains MAPK-Axis Adaptive and Acquired Alterations in Patients with RAS-Mutant Tumors
The article discusses Atebimetinib's role in inhibiting MEK and its effects on RAS-mutant tumors. It highlights the drug's potential to constrain adaptive and acquired alterations in the MAPK axis. However, specific details about clinical outcomes or study results are not provided.
Read more →IMRXImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Immuneering Corporation presented new genetic data at the 2026 AACR Annual Meeting, highlighting the potential of their drug, atebimetinib, in improving survival for pancreatic cancer patients. The findings indicate that atebimetinib-treated tumors show rare mutations associated with drug resistance, suggesting that it may provide more durable treatment efficacy compared to conventional therapies. The company is expected to initiate a pivotal Phase 3 trial of atebimetinib in combination with chemotherapy in mid-2026, further supporting the drug's promising profile in oncology.
Read more →IMRXNora Bruno
Nora Bruno has joined Immuneering, bringing over 25 years of experience in life sciences. Her career includes significant roles in biotechnology, medical devices, and pharmaceutical drug development. She has a strong background in Quality leadership and has worked with various biopharmaceutical companies. Ms. Bruno holds multiple degrees related to her field.
Read more →IMRXImmuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation announced that CEO Ben Zeskind will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The company is focused on developing Deep Cyclic Inhibitors, with its lead candidate, atebimetinib, targeting various cancer indications. The pivotal Phase 3 trial for atebimetinib is expected to begin mid-2026.
Read more →IMRXMarch 2026 – Brew Markets
The article discusses the use of cookies on a website to enhance user experience. It explains how cookies help in recognizing returning users and collecting analytics data to improve the site. There are no specific news events or updates related to IMRX mentioned in the text.
Read more →IMRXMarch 2026 – The BioReport Podcast
The article discusses the use of cookies on a website to enhance user experience. It outlines the necessity of enabling certain cookies for saving user preferences and mentions the use of Google Analytics for collecting anonymous visitor data. However, it does not provide any specific news or updates related to IMRX.
Read more →IMRXImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering Corporation announced it will present data on atebimetinib at the AACR Annual Meeting in April 2026. The presentation will focus on the drug's ability to shrink tumors durably and mitigate resistance mechanisms in RAS-mutant solid tumors. The findings suggest that atebimetinib may provide a more sustained clinical benefit compared to conventional MAPK inhibitors.
Read more →IMRX▲ +7%on this news
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic
Immuneering Corporation reported strong financial results for the fourth quarter and full year 2025, highlighting a 64% overall survival rate in its Phase 2a trial of atebimetinib combined with mGnP in pancreatic cancer patients. The company plans to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026 after securing FDA and EMA alignment. Despite a substantial cash position and upcoming clinical milestones, Immuneering continues to experience financial losses and rising administrative costs. Nevertheless, their drug candidate, atebimetinib, shows promise in improving overall survival through innovative mechanisms.
Read more →IMRXImmuneering to Present at the Leerink Global Healthcare Conference
Immuneering Corporation will present at the Leerink Global Healthcare Conference on March 9-11, 2026, in Miami. CEO Ben Zeskind will discuss the company's pipeline and business strategy. Immuneering focuses on developing Deep Cyclic Inhibitors to enhance cancer patient survival. The lead candidate, atebimetinib, targets MAPK pathway-driven tumors and is set for a pivotal Phase 3 trial.
Read more →IMRXFebruary 2026 – Healthcare Brew
The article primarily discusses the use of cookies on a website, emphasizing user privacy and analytics. It highlights the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for tracking site performance. There are no specific news events or developments related to IMRX.
Read more →IMRXImmuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Immuneering Corporation (Nasdaq: IMRX) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, scheduled for February 25-26, 2026. CEO Ben Zeskind and CSO Brett Hall will present the company's pipeline, platform, and business strategy. Immuneering focuses on late-stage clinical oncology and is developing a new class of cancer therapies, with atebimetinib as its lead product candidate slated for evaluation in a Phase 3 trial for pancreatic cancer. The presentation will be available via webcast for interested investors.
Read more →IMRXPatrick Xin
Patrick Xin has been appointed as Senior Director of Clinical Data Management at Immuneering. He will oversee the company's clinical data strategy and execution for global programs. Xin brings a wealth of experience from his previous roles at Arcturus Therapeutics and NYU Langone Health, along with a strong educational background in computer science and biochemistry.
Read more →IMRXVinny Hayreh, MD
Vinny Hayreh, MD, is a seasoned physician executive specializing in oncology clinical development. She leads oncology programs at Immuneering and has previously held senior roles at notable pharmaceutical companies such as Janssen and Bristol Myers Squibb. Additionally, she is the founder of a consulting firm focused on clinical strategy and pharmacovigilance.
Read more →IMRXLoretta Sullivan, MD, MPH
Loretta Sullivan, MD, MPH, is a seasoned leader in global health with a rich background in the biopharmaceutical industry. She has worked with major companies like Genentech and Lilly, and has extensive experience as an epidemiologist with organizations such as the CDC and WHO. Dr. Sullivan's education includes degrees from Dartmouth, UCLA, and the University of Colorado. She is also a veteran and resides in Denver with her family.
Read more →IMRXCourtney Dugan
Courtney Dugan has joined Immuneering as Vice President, Head of Investor Relations and Corporate Communications. With 18 years of experience in the healthcare sector, she has previously worked with Y-mAbs Therapeutics, Olema Oncology, and Johnson & Johnson. Dugan's expertise includes investor relations, corporate communications, and reputation management.
Read more →IMRX▲ +5.9%on this newsshared move
February 2026 – Pharmacy Times
The article primarily discusses the privacy overview and cookie usage on the Pharmacy Times website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for collecting visitor data. There are no specific news events or updates related to IMRX.
Read more →IMRXFebruary 2026 – CURE Today
The article primarily discusses the website's cookie policy and privacy overview. It emphasizes the importance of enabling necessary cookies for optimal user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website.
Read more →IMRXFebruary 2026 – Pharmaphorum
The article primarily discusses the website's privacy policy and cookie usage. It emphasizes the importance of necessary cookies for user experience and mentions the use of Google Analytics for site improvement. However, it does not provide any relevant information about IMRX or the biopharma sector.
Read more →IMRXJanuary 2026 – Pharmacy Times
The article discusses the use of cookies on a website to enhance user experience. It emphasizes the importance of enabling necessary cookies for saving preferences and mentions the use of Google Analytics for collecting anonymous visitor data. However, it does not provide specific details about any biopharma news or events.
Read more →IMRXJanuary 2026 – Targeted Oncology
The article primarily discusses the privacy and cookie policies of a website, emphasizing the importance of user experience and analytics. It outlines how cookies are utilized to enhance site functionality and track visitor engagement. There are no specific biopharma news updates or events mentioned.
Read more →IMRXJanuary 2026 – Rare Cancer
The article provides a brief overview of cookie usage and privacy settings on a website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for data collection. However, it does not present any specific news or developments related to rare cancer or the ticker IMRX.
Read more →IMRX▼ -43.2%on this news
January 2026 – Fierce Biotech
The article primarily discusses the privacy overview and cookie usage on a website, emphasizing the importance of user experience and analytics. It highlights the necessity of enabling cookies for optimal functionality and mentions the use of Google Analytics for collecting visitor data. However, it lacks specific news related to the ticker IMRX.
Read more →IMRX▼ -43.2%on this newsshared move
January 2026 – FirstWord Pharma
The article discusses the use of cookies on a website to enhance user experience. It highlights the importance of enabling necessary cookies for saving user preferences and mentions the use of Google Analytics for collecting anonymous visitor data. Overall, the content focuses on privacy and user experience rather than specific biopharma news.
Read more →IMRX▼ -43.2%on this newsshared move
January 2026 – Endpoints News
The article primarily discusses the use of cookies on a website to enhance user experience. It outlines the necessity of enabling certain cookies for saving user preferences and mentions the use of Google Analytics for collecting anonymous visitor data. However, it does not provide specific news or updates related to IMRX.
Read more →IMRX▲ +24%on this news· ran to -37% by day 3shared move
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation announced a promising 64% overall survival rate at 12 months from its Phase 2a trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The median overall survival has not yet been reached, indicating potential for durable clinical benefits. The company is preparing to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026, following favorable discussions with the FDA and EMA. Continued favorable tolerability has been observed, with no new safety concerns reported.
Read more →IMRXLaurie Keating, J.D.
Laurie Keating, J.D., has been a member of the Board of Directors at IMRX since March 2021. She has a strong background in the biopharma sector, having served in executive roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Additionally, she chairs the board of PepGen Inc. and has served on various other boards.
Read more →IMRXDouglas A. Lauffenburger, Ph.D.
The article primarily discusses the privacy overview and cookie usage on the website. It mentions the necessity of enabling cookies for optimal user experience and the use of Google Analytics for tracking visitor data. However, it lacks specific details about Douglas A. Lauffenburger, Ph.D.
Read more →IMRXJordan Berlin, M.D., FASCO
The article provides an overview of the website's privacy policy and cookie usage. It emphasizes the importance of enabling necessary cookies for optimal user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to enhance website functionality.
Read more →IMRXVincent Chung, M.D., FACP
The article provides an overview of the privacy policy related to cookie usage on the website. It emphasizes the necessity of enabling certain cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. There are no specific updates or news regarding Vincent Chung, M.D., FACP.
Read more →IMRXDiana Hausman, M.D.
Dr. Diana Hausman has been a member of the Board of Directors since January 2022 and currently serves as a consulting Chief Medical Officer at Reverb Therapeutics. She has held significant roles in various biotech firms, including Zentalis Pharmaceuticals and Link Immunotherapeutics. Dr. Hausman's career spans multiple therapeutic areas, showcasing her extensive expertise in the field.
Read more →IMRXPeter Feinberg
Mr. Peter Feinberg has been a member of the Board of Directors since January 2021. He is a founding member of Boxcar Partners and has significant experience in biotechnology through various leadership roles in multiple companies. His background includes over three decades in financial services, enhancing his qualifications in the biotech sector.
Read more →IMRXBob Carpenter, M.S., MBA
Bob Carpenter has been a member of the Board of Directors since May 2009 and served as Chair until December 2023. He is the Chairman and Co-Founder of Olaris, Inc. and has a rich history in the biotechnology sector, having held executive roles in various companies, including Moderna and Genzyme. His educational credentials include degrees from the U.S. Military Academy, Stanford University, and Harvard Business School.
Read more →IMRXAdam Shiell, PharmD
Dr. Adam Shiell brings over a decade of regulatory affairs experience to Immuneering, specializing in oncology drug development. His previous role at Flatiron Health involved leading clinical research with a focus on real-world evidence. Shiell's extensive background includes various regulatory roles at Eli Lilly & Company, supporting both early and late-phase oncology compounds.
Read more →IMRXDoris Perez Diaz
Doris Perez Diaz is a seasoned professional in clinical research with over ten years of experience. She has a strong background in project management, regulatory compliance, and clinical operations, having worked at various levels in the industry. Her career began in dermatopathology, and she has since transitioned to biotech, gaining insights across all phases of clinical trials.
Read more →IMRXMarty Hughes, Ph.D.
Dr. Marty Hughes, Ph.D., has joined Immuneering as the head of manufacturing process development. He brings a wealth of experience from his previous roles at Cidara Therapeutics, where he oversaw the development of REZZAYO™, and at Boehringer-Ingelheim. Dr. Hughes holds a Ph.D. in Organic Chemistry and has a strong background in clinical chemistry.
Read more →IMRXAnastasia Gutierrez, M.D.
Dr. Anastasia Gutierrez is a seasoned clinical research leader with two decades of experience in drug development, particularly in early phase Oncology. She holds an MD from Smolensk State Medical Academy and has worked extensively with clinical CROs. Currently, she leads Clinical and Safety Operations at Bellicum Pharmaceuticals.
Read more →IMRXElisabeth Madec Foley
Elisabeth Madec Foley has joined IMRX, bringing over 18 years of experience in clinical trials from both CRO and Biotech sectors. Her expertise includes project management and leading clinical operations, with a focus on early Phase 1 oncology trials. Foley's educational background includes a Bachelor of Science in Cell and Molecular Biology from Tulane University.
Read more →IMRXDanielle Flannery
Danielle Flannery joined Immuneering's clinical team in October 2022, bringing extensive experience from her previous roles in pediatrics and dermatology. She has worked as a Lead Medical Communications Specialist at a clinical research organization, emphasizing reporting and patient education. Flannery holds a bachelor's degree in international studies and public health from Indiana University.
Read more →IMRXAndrew Conrad, Ph.D.
Dr. Andrew Conrad has joined Immuneering, bringing over 13 years of experience in analytical, formulation, and manufacturing process development. He previously held significant roles at Hikma Pharmaceuticals, where he led product development, and at Boehringer Ingelheim. Dr. Conrad holds a B.S. in Chemistry and a Ph.D. in Physical Chemistry from Kent State University.
Read more →IMRXJenny Zhang, Ph.D.
Dr. Jenny Zhang, Ph.D., specializes in extracting insights from genomic data using advanced data science techniques. With a fellowship at The Data Incubator, she applied distributed computing and machine learning to analyze large datasets. Her academic credentials include a B.S. from MIT and a Ph.D. in Genetics from Duke, where she focused on lymphoma research.
Read more →IMRXAmy Yamamura
Ms. Amy Yamamura brings years of experience in disease models related to inflammation, immunology, and oncology. She studied Cellular Neuroscience and Psychology at Colgate University, equipping her with a strong academic background for her role.
Read more →IMRXFrank Wang, Ph.D.
Dr. Frank Wang, Ph.D., has extensive experience in computational biology, focusing on human diseases. He earned his Ph.D. in Bioinformatics and has worked on identifying biomarkers for breast cancer and systemic sclerosis. His research includes drug repositioning and classification of patient subsets, utilizing various biological data types.
Read more →IMRXKurt Walsh
Kurt Walsh is a scientist and engineer with a solid academic background. He earned a B.Sc in Biomolecular Engineering from UC Santa Cruz, focusing on small molecule drugs' effects on chondrocytes. He later obtained an M.S. in Biomedical Engineering from UC San Diego, specializing in tissue engineering and cell-ECM dynamics.
Read more →IMRXAnna Travesa, Ph.D.
Dr. Anna Travesa has a rich background in cancer research, with expertise in genetics and tumor cell biology. Her work at Scripps Research and UCSD led to significant discoveries in cell proliferation and malignant transformation. Additionally, she has played a vital role in advancing preclinical and drug development programs, promoting collaboration and quality in drug discovery.
Read more →IMRXElisabeth Standard
Elisabeth Standard, a professional in biotechnology quality management, has joined Immuneering. With a Master's degree from Binghamton University, she has a strong background in drug discovery and quality management systems. Her previous work includes significant contributions at BioArkive, where she supported accreditation efforts and critical projects. Standard will now aid in advancing Immuneering's oncology drug pipeline.
Read more →IMRXJennifer Quach
Jennifer Quach has been serving as Operations Assistant at Immuneering since April 2023. With a B.S. in Biology from UC San Diego, she has experience in lab work and administrative tasks. Quach aims to leverage her knowledge to positively impact the community while supporting lab operations within cross-disciplinary teams.
Read more →IMRXFrancisco Piña, Ph.D.
Dr. Francisco Piña has joined Immuneering, bringing extensive expertise in cell and molecular biology, biochemistry, and genetics. He previously conducted postdoctoral research at UCSD, focusing on the relationship between cell cycle progression and endoplasmic reticulum function. Dr. Piña holds a Ph.D. from Stanford University, where he studied ER-localized proteins.
Read more →IMRXSreeraj Pillai, Ph.D.
Dr. Sreeraj Pillai is a seasoned cancer biologist with over 16 years of experience in both basic and translational research. His focus has been on Disseminated Tumor Cells (DTCs) in breast cancer, exploring their impact on disease progression and metastasis. He holds a Ph.D. from India and has conducted postdoctoral research at prestigious institutions in St. Louis.
Read more →IMRXAlex Peterson
The article discusses the privacy overview and cookie usage on a website. It highlights the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. The content is focused on website functionality rather than specific news events.
Read more →IMRXMatthew Nord, Ph.D.
Dr. Matthew Nord is a cell biologist with a focus on the cell cycle and protein roles during interphase and mitosis. He holds a B.S. in Biochemistry and Cell Biology and a Ph.D. in Cell Biology from UC San Diego. His research investigates the interactions between nuclear transport receptors and the small GTPase RAN, which are crucial for nuclear pore complex regulation.
Read more →IMRXBrian Nguyen
Brian Nguyen holds a B.S. in Biochemistry from UCLA and has extensive experience in laboratory settings. He started as a lab assistant at UC San Diego, later becoming a lab manager. His career progressed into the industry, focusing on high-throughput screening drug discovery, and he joined Immuneering in 2022.
Read more →IMRXPraveen Nair, Ph.D.
Dr. Praveen Nair has joined Immuneering, bringing extensive leadership experience in drug discovery and translational research. He co-founded BioArkive and served as its CEO, focusing on oncology research support. His previous roles include key scientific leadership at Asellus Therapeutics and research support at Molecular Response. Dr. Nair holds a Ph.D. from the University of Georgia.
Read more →IMRXKyra Liebson
Kyra Liebson is a dual-degree holder with a Bachelor of Science in Cell and Molecular Biology from the University of South Florida and a Bachelor of Science in Marketing from SUNY Oswego. She has researched B-cell lymphoma proliferation and has a strong background in marketing and advertising. Liebson's commitment to excellence and passion for science and operations contribute to her role at Immuneering.
Read more →IMRXSarah Kolitz, Ph.D.
Dr. Sarah Kolitz has joined the team, bringing valuable expertise in biological mechanisms. She completed her postdoctoral research in Biological Engineering at MIT and holds a Ph.D. in Biophysics and Biophysical Chemistry from Johns Hopkins University. Her background is expected to enhance the team's capabilities.
Read more →IMRXPeter King, Ph.D.
Dr. Peter King is a seasoned pharmaceutical professional with over 16 years of experience in drug discovery and development. He has worked with renowned companies like Janssen R&D and SmithKline Beecham, contributing significantly to preclinical oncology and metabolic disorders. Dr. King holds a B.Sc. in Biological Sciences and a Ph.D. in Diabetes and Endocrinology.
Read more →IMRXJason Kim
Mr. Jason Kim is focused on leveraging technology to enhance research and development in biomedicine. He holds an M.S. in Biomedical Informatics from NYU and has extensive experience as a software implementation consultant in the life sciences sector. His academic credentials also include a B.S./M.S. in Biomedical Engineering from Northwestern University.
Read more →IMRXJessie Haupt
Jessie Haupt, with a B.A. in History from UC Santa Cruz and a Certificate of Paralegal Studies from UC Berkeley Extension, has transitioned from a paralegal role to a position in the Operations Team. In her current role, she is responsible for laboratory procurement and ensuring efficient daily lab operations.
Read more →IMRXJason Funt, Ph.D.
Dr. Jason Funt, Ph.D., specializes in synthesizing insights from complex data. He obtained his Ph.D. in Computational and Systems Biology from MIT, where his research centered on understanding drug resistance in the pathogen Candida albicans through genomic and transcriptomic profiling.
Read more →IMRXKevin D. Fowler, Ph.D.
Dr. Kevin D. Fowler has joined Immuneering, bringing significant expertise in biology and computational biology. He earned his Ph.D. in Chemical Engineering from MIT, where his research concentrated on computational immunology and signal integration in immune cell biology. Additionally, he has experience conducting research at Harvard Medical School.
Read more →IMRXBart DeCorte, Ph.D.
Dr. Bart DeCorte has been appointed as VP of Chemistry at Immuneering since April 2025. He brings over 20 years of experience from Johnson & Johnson, where he contributed to various therapeutic areas. Notably, he co-invented IMM-1-104, currently in clinical evaluation for advanced solid tumors, and INTELENCE, an FDA-approved HIV treatment. His academic background includes degrees in Bioengineering and organic chemistry.
Read more →IMRXCaitlin Dao
Caitlin Dao is an Associate Scientist at Immuneering, where she plays a key role in high-throughput screening and lead compound translation. She has a Master's degree in Chemistry from Queen's University and holds Bachelor's degrees in Biochemistry and Molecular Biology from the University of Toronto. Her expertise enhances the company's research capabilities.
Read more →IMRXAmy Axel
Ms. Amy Axel is a skilled scientist with a strong background in both academia and the pharmaceutical sector. She has worked at notable institutions such as Nationwide Children’s Hospital and Janssen/J&J, focusing on tumor microenvironments and biomarker strategies in clinical trials. Axel holds a BSc in Molecular Genetics from Ohio State University.
Read more →IMRXHemalatha Athawale
Hema Athawale has recently graduated from California State University, San Marcos, earning a Master's Degree in Biotechnology. She has gained practical lab experience through her involvement in an epigenetics project and served as a teacher's assistant in molecular biology and DNA/RNA technology labs. Athawale has also worked as an educator in India and is now a full-time Research Associate at Immuneering.
Read more →IMRXNaseem Alkaabi
Naseem Alkaabi is a Senior Research Associate with expertise in biotechnology and cancer research. She specializes in various techniques including mammalian cell culture and immunoassays. Her contributions span academic and industry settings, focusing on cancer immunotherapy and drug discovery. Naseem holds a Bachelor's degree in Medicine and Health Sciences and has formal training in Clinical Trials.
Read more →IMRXStephen Sebastian, CPA
Stephen Sebastian has joined Immuneering, bringing over 13 years of experience in technical accounting and financial reporting. Previously, he worked as a Director at PwC, where he specialized in SEC reporting. His career began in the Pharma/Life Sciences Assurance practice, providing audit services and advising on financial reporting requirements.
Read more →IMRXScott Nguyen
Scott Nguyen has been appointed as the Head of Information Technology at Immuneering, starting in August 2023. He previously served as IT Director at Spectrum Pharmaceuticals and led the IT Infrastructure department at Halozyme Therapeutics. His experience spans over 16 years in various IT leadership roles, focusing on enterprise systems and IT policy development.
Read more →IMRXTyler Mead
Mr. Tyler Mead has a notable background in the Pharma and Life Sciences sectors, having started his career at PwC. He has provided audit services and guidance on compliance and financial reporting. Mr. Mead holds a B.S. in Accounting from Providence College and is a Certified Public Accountant in New Jersey.
Read more →IMRXMelissa Martin
Ms. Melissa Martin brings extensive experience in office administration and customer relations across various sectors. She has a solid background in marketing, human resources, and finance, complemented by a B.S. in Communications from Fitchburg State University. Her diverse skill set positions her well for roles that require multifaceted expertise.
Read more →IMRXDominique Hinds
Dominique Hinds has been working as an Administrative Assistant at Immuneering since May 2023. Previously, she served in the United States Navy as an Operations Specialist on the USS Essex LHD-2, where she managed the operational schedule for over 5,000 personnel. Hinds is currently studying for a B.A. in Business Administration.
Read more →IMRXPaula George, CPA
Paula George, CPA, has joined Immuneering, bringing a wealth of experience from her previous roles. She began her career at PwC, specializing in Pharma/Life Sciences Assurance. Before Immuneering, she led FinTech Accounting at Advent Intermodal Solutions, focusing on digital payments and international growth. Ms. George holds a B.S. in Accounting from Rutgers University.
Read more →IMRXWill Drew
Mr. Drew joins Immuneering with over 15 years of experience in cloud computing operations, specializing in high performance computing and big data. He has a strong background in software engineering and cloud operations, focusing on security. Driven by personal loss, he is committed to leveraging his skills to advance cancer treatment.
Read more →IMRXDominic Capasso, J.D.
Dominic Capasso has been appointed as Associate General Counsel at Immuneering as of May 2023. He brings extensive experience from his previous role as Vice President, Corporate Counsel and Secretary at Evelo Biosciences. Capasso has also worked at prestigious law firms, including Cooley LLP and Cravath, Swaine and Moore LLP, focusing on corporate transactional and governance matters.
Read more →IMRXPedram Banishahabadi
Pedram Banishahabadi brings a decade of IT experience to Immuneering, showcasing a strong passion for technology and innovation. His prior roles include Systems Engineer at various companies, highlighting his diverse expertise. Banishahabadi holds an MBA and an M.S. in engineering, along with a certification in cloud engineering.
Read more →IMRXDamaris Arcila
Damaris Arcila is an experienced accounting professional with over two decades in the field. She oversees accounting operations and accounts payable at Immuneering, contributing significantly to the company's financial management.
Read more →IMRXChristian Alaia, CPA
Christian Alaia, CPA, is a finance expert with a strong background in the pharmaceutical industry. He has worked at notable companies, including Sanofi and Immunomedics, where he contributed to the commercialization of Trodelvy. His career began at Sax LLP, and he holds a BS in Accounting from SUNY Albany.
Read more →IMRX▲ +6.6%on this newsshared move
Tom Schall, Ph. D.
Dr. Tom Schall has been a member of the Board of Directors since March 2024. He is known for founding ChemoCentryx, where he served as President and CEO for 25 years until its acquisition by Amgen in 2022. His prior experience includes roles at DNAX Research Institute and Genentech, where he contributed to key discoveries in chemokine research.
Read more →IMRX▲ +6.6%on this newsshared move
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Immuneering Corporation will announce 12-month overall survival data from its Phase 2a trial of atebimetinib combined with mGnP for first-line pancreatic cancer on January 7, 2026. The company expresses confidence in the drug's potential to enhance patient outcomes. The data will be shared during a conference call and webcast.
Read more →IMRX▲ +8.1%on this newsshared move
December 2025 – Clinical Trials Arena
The article provides an overview of cookie usage on a website, emphasizing user experience and analytics. It mentions the importance of enabling necessary cookies for saving preferences. However, it lacks specific information regarding clinical trials or any related updates.
Read more →IMRXDecember 2025 – Rare Cancer News
The article primarily discusses the website's privacy overview and cookie usage. It emphasizes the importance of necessary cookies for user experience and mentions the use of Google Analytics for collecting anonymous visitor data. However, no specific news related to rare cancer or the ticker IMRX is provided.
Read more →IMRXLeah Neufeld
Leah Neufeld has been appointed as the Chief People Officer of IMRX since October 2022. She has a rich background in human resources, having previously worked at Luzsana Biotechnology, Prevail Therapeutics, and Intercept Pharmaceuticals. Neufeld's career spans various leadership roles in notable biopharma companies, contributing significantly to their HR strategies.
Read more →IMRXMallory Morales, CPA
Mallory Morales has been appointed as Senior Vice President of Finance, Chief Accounting Officer, and Treasurer at IMRX since February 2026. She has a robust background in finance, previously serving in various roles at Gilead Sciences and Immunomedics. Morales is a CPA and has a strong educational foundation in accounting.
Read more →IMRXIgor Matushansky, M.D., Ph.D.
Dr. Igor Matushansky has been appointed as Chief Medical Officer at Immuneering, bringing a wealth of experience from previous roles at notable companies like Sail Biomedicines and Ipsen S.A. He has a strong background in oncology development, having overseen significant projects leading to drug approvals. His academic credentials include a Ph.D. in molecular biology and extensive clinical experience in treating sarcoma patients.
Read more →IMRXBrett Hall, Ph.D.
Dr. Brett Hall has been the Chief Scientific Officer at IMRX since November 2019. He has a rich background in biotechnology, having held leadership positions at BioArkive, Asellus Therapeutics, and Medimmune. Dr. Hall's expertise includes drug development, translational medicine, and he has contributed significantly to the field through publications and patents.
Read more →IMRXMichael Bookman, J.D.
Michael Bookman has been appointed Chief Legal Officer and Secretary of IMRX since January 2023, bringing significant legal expertise from his previous roles at Frequency Therapeutics and Latham & Watkins. He has a strong educational background, holding a B.B.A. in finance and a J.D. from reputable institutions. Bookman's involvement with the Girl Scouts of Eastern Massachusetts showcases his commitment to community service.
Read more →IMRXBen Zeskind, Ph.D., MBA
Dr. Ben Zeskind has been a pivotal leader at IMRX since its founding in 2008. He holds an S.B. in electrical engineering and computer science from MIT, a Ph.D. in bioengineering, and an MBA from Harvard Business School, where he earned the distinction of Baker Scholar.
Read more →IMRXImmuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Immuneering Corporation is set to begin dosing patients in a global Phase 3 trial for atebimetinib in first-line metastatic pancreatic cancer by mid-2026. The company has completed End-of-Phase 2 interactions with the FDA and received scientific advice from the EMA, achieving alignment on trial design. The trial will evaluate atebimetinib in combination with modified gemcitabine and nab-paclitaxel, with a primary endpoint of overall survival.
Read more →IMRXImmuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index, effective prior to market open on December 22, 2025. This addition highlights the company's eligibility and performance in the biotechnology sector. Immuneering focuses on developing novel cancer therapies, including its lead product candidate, atebimetinib, which is intended for treating various cancer indications. With a Phase 3 trial planned for mid-2026, the company aims to enhance cancer patients' quality of life.
Read more →IMRXImmuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Immuneering Corporation reported strong financial results for Q3 2025, highlighting an impressive 86% overall survival rate in pancreatic cancer patients treated with atebimetinib. The company raised $225 million, ensuring funding through 2029, and received a U.S. patent for atebimetinib. Additionally, notable patient responses were documented, supporting the drug's potential in cancer treatment.
Read more →IMRXOctober 2025 – BioTuesdays
The article primarily discusses the privacy overview and cookie usage on the website. It emphasizes the necessity of enabling cookies for optimal user experience and mentions the use of Google Analytics for tracking site visitors. However, it lacks specific news or updates related to IMRX.
Read more →IMRXOctober 2025 – BiotechTV
The article primarily discusses the privacy policy and cookie usage on the BiotechTV website. It emphasizes the importance of enabling necessary cookies for optimal user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website.
Read more →IMRXOctober 2025 – Let’s Win Pancreatic Cancer
The article primarily discusses privacy policies and cookie usage on a website, with no substantial information about pancreatic cancer or related initiatives. It emphasizes the importance of user experience and analytics but fails to provide any updates or insights into the fight against pancreatic cancer.
Read more →IMRXOctober 2025 – Targeted Oncology
The article discusses the use of cookies on a website to enhance user experience. It highlights the importance of enabling necessary cookies for saving user preferences and mentions the use of Google Analytics for collecting anonymous visitor data. However, it does not provide specific news or updates related to IMRX.
Read more →IMRXOctober 2025 – OncLive
The article primarily discusses the use of cookies on the website, emphasizing the importance of user privacy and analytics. It highlights the necessity of enabling cookies for optimal user experience and mentions the use of Google Analytics for tracking site performance. However, there are no specific news events or developments related to IMRX.
Read more →IMRX▼ -16.5%on this news
Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results
The updated Phase 2 results for Atebimetinib (IMM-1-104) combined with modified Gemcitabine/Nab-Paclitaxel (mGnP) indicate significant improvements in overall survival for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The therapy also shows a favorable tolerability profile, suggesting its potential as a viable treatment option.
Read more →IMRX▼ -16.5%on this newsshared move
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Immuneering Corporation will host a conference call on September 29, 2025, to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib combined with mGnP in first-line pancreatic cancer patients. The data, which shows promising results, will also be presented at the PanCAN Scientific Summit 2025. The call aims to engage the community in understanding these important findings.
Read more →IMRX▼ -5.7%on this news· ran to -17% by day 3shared move
September 2025 – OncLive
The article primarily discusses the privacy overview and cookie usage on the website. It emphasizes the necessity of enabling cookies for optimal user experience and mentions the use of Google Analytics for collecting visitor data. There are no specific news events or developments related to IMRX.
Read more →IMRX▼ -13.3%on this news· ran to -24% by day 3shared move
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Immuneering Corporation has announced the pricing of its underwritten public offering of Class A common stock, aiming to raise approximately $175 million. The offering includes an option for underwriters to purchase additional shares. Concurrently, Sanofi will purchase shares in a private placement. Proceeds will support the development of Immuneering's product candidates.
Read more →IMRX▼ -13.3%on this news· ran to -24% by day 3shared move
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Corporation announced a proposed underwritten public offering of Class A common stock and pre-funded warrants. Concurrently, Sanofi will purchase $25 million in shares as part of a private placement. The proceeds from both transactions are intended to support the development of Immuneering's product candidates. However, the offering is subject to market conditions and may not be completed as planned.
Read more →IMRX▲ +7.5%on this news· ran to -21% by day 3shared move
September 2025 – Endpoints News
The article primarily discusses the privacy overview and cookie usage on a website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. There are no specific news events or developments related to IMRX.
Read more →IMRXDeep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in Ras-Mutant Cancers
The article discusses the potential of deep cyclic inhibition of MEK as a novel approach for treating Ras-mutant cancers. It highlights the promise of this method in creating durable and safe combination therapies. However, specific details about the research findings or clinical implications are not provided.
Read more →IMRX▲ +5.7%on this news· ran to +18% by day 3shared move
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Immuneering Corporation has appointed Dr. Thomas Schall as Chairman of the Board. Dr. Schall, a seasoned biotech executive, is expected to leverage his extensive experience in drug development to guide Immuneering through late-stage development of its lead candidate, atebimetinib. His appointment comes as the company prepares for significant upcoming data announcements and pivotal studies.
Read more →IMRX▲ +5.7%on this news· ran to +18% by day 3shared move
September 2025 – The Scientist
The article primarily discusses cookie usage and privacy settings on a website. It emphasizes the importance of enabling necessary cookies for optimal user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website.
Read more →IMRX▼ -12.3%on this news
Immuneering Announces Closing of $25 Million Private Placement
Immuneering Corporation announced the successful closing of a $25 million private placement aimed at supporting its oncology drug development. The placement involved the sale of unregistered shares and warrants to institutional investors. The company is focused on developing its lead candidate, atebimetinib, which is currently in a Phase 2a trial for advanced solid tumors.
Read more →IMRX▲ +21.7%on this newsshared move
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Immuneering Corporation has announced a clinical supply agreement with Eli Lilly to evaluate atebimetinib in combination with olomorasib in a Phase 2 trial for advanced non-small cell lung cancer. This collaboration aims to explore the potential of a dual-targeted approach to improve treatment outcomes. Preclinical studies have shown promising results, indicating enhanced tumor regression and prolonged survival.
Read more →IMRX▲ +35%on this news· ran to +73% by day 3shared move
Immuneering Announces $25 Million Private Placement
Immuneering Corporation announced a $25 million private placement aimed at institutional and accredited investors. The proceeds from this placement will support the ongoing Phase 2a trial of their product candidate, atebimetinib, targeting pancreatic cancer. Notably, recent data showed a 94% overall survival rate at 6 months among patients treated with atebimetinib in combination with mGnP. This remarkable response rate has attracted significant interest from investors and pharmaceutical companies alike.
Read more →IMRXImmuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N 34) treated with atebimetinib + m
Immuneering Corporation reported promising financial results for Q2 2025, highlighting a 94% overall survival rate observed in their Phase 2a trial for atebimetinib in first-line pancreatic cancer patients. The company anticipates sharing updated overall survival and progression-free survival data in Q3 2025. Additionally, Immuneering received a new composition of matter patent for atebimetinib, providing expected exclusivity until 2042. The company has submitted a meeting request to the FDA to plan a pivotal trial for atebimetinib, which is expected to begin in 2026.
Read more →IMRXJuly 2025 – Pharmaceutical Executive
The article appears to focus on privacy and cookie usage on a website, detailing how cookies enhance user experience by remembering preferences and collecting analytics data. However, it lacks specific news related to the biopharma industry or the ticker IMRX.
Read more →IMRX▲ +11.3%on this news
July 2025 – Forbes
The article primarily discusses the privacy overview and cookie usage on a website. It highlights the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for tracking visitor data. There are no specific news events or developments related to IMRX.
Read more →IMRXJuly 2025 – PharmaVoice
The article primarily discusses the privacy overview and cookie usage on a website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for collecting anonymous visitor data. There are no specific news events or updates related to IMRX.
Read more →IMRX▲ +52.2%on this news
June 2025 – Targeted Oncology
The article primarily discusses privacy policies related to cookie usage on a website. It emphasizes the importance of enabling necessary cookies for optimal user experience and mentions the use of Google Analytics for tracking visitor data. However, it does not provide specific news or updates related to the ticker IMRX.
Read more →IMRX▲ +52.2%on this newsshared move
June 2025 – OncLive
The article primarily discusses the use of cookies on the website, highlighting their importance for user experience and analytics. It emphasizes the necessity of enabling certain cookies to save user preferences. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data.
Read more →IMRX▼ -23.2%on this newsshared move
June 2025 – Fierce Biotech
The article primarily focuses on the website's privacy and cookie policies rather than providing any significant updates or news related to the biopharma industry. It mentions the use of cookies for user experience and analytics but does not cover any specific events or developments in the field. Overall, it lacks relevant biopharma content.
Read more →IMRX▼ -23.2%on this newsshared move
June 2025 – Cancer Network
The article discusses the use of cookies on a website to enhance user experience. It outlines how cookies help in recognizing returning users and collecting analytics data to improve website functionality. However, it does not provide any specific news or developments related to IMRX.
Read more →IMRX▼ -23.2%on this newsshared move
June 2025 – FirstWord Pharma
The article primarily discusses privacy and cookie usage on a website, emphasizing the importance of user experience and analytics. It outlines how cookies function to enhance site performance and user preferences. However, it does not provide any specific news or updates related to IMRX.
Read more →IMRX▼ -23.2%on this newsshared move
June 2025 – Endpoints News
The article primarily discusses the use of cookies on a website to enhance user experience. It outlines the necessity of enabling certain cookies for functionality and mentions the use of Google Analytics for collecting anonymous visitor data. However, it lacks specific news related to IMRX.
Read more →IMRXImmuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-
Immuneering Corporation reported its first quarter 2025 financial results, highlighting positive developments in its Phase 2a trial of IMM-1-104 for pancreatic cancer. The trial showed encouraging patient responses, including complete and partial responses in various treatment settings. The company extended its cash runway into 2026 and announced the appointment of Dr. Igor Matushansky as Chief Medical Officer to lead clinical efforts. However, it also reported a net loss of $15.0 million, indicating ongoing financial challenges.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging resp
Immuneering Corporation has reported positive updates from its Phase 2a trial of IMM-1-104, particularly in pancreatic cancer, where combination therapies showed promising response rates. The company has secured a clinical trial supply agreement with Regeneron Pharmaceuticals for further studies in non-small cell lung cancer. Additionally, Immuneering has appointed Dr. Igor Matushansky as Chief Medical Officer to lead future clinical activities. While the company's cash runway extends into 2026, it has also reported a significant increase in net losses compared to the previous year.
Read more →IMRXPotential anti-cachexia properties of novel dual-MEK inhibitor IMM-1-104
The article discusses the potential anti-cachexia properties of the novel dual-MEK inhibitor IMM-1-104. However, it lacks specific details or findings related to the drug's efficacy or clinical implications. The content primarily focuses on website privacy and cookie settings rather than the drug itself.
Read more →IMRX▼ -6.6%on this news
Phase 1 Interim Population PK/PD Modeling and Recommended Phase 2 Dose Exploration for IMM-1-104, A Novel Concept Oral Deep Cyclic Inhibitor of MEK
The article discusses the Phase 1 interim population pharmacokinetic/pharmacodynamic modeling and the recommended Phase 2 dose exploration for IMM-1-104, a novel oral deep cyclic inhibitor of MEK. It highlights the importance of this research in understanding the drug's efficacy and safety profile. However, specific results and implications are not detailed in the provided text.
Read more →IMRX▼ -6.6%on this newsshared move
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First
Immuneering Corporation reported its third quarter 2024 financial results, highlighting positive initial data for IMM-1-104 in a Phase 2a clinical trial for pancreatic cancer. The company has received FDA Orphan Drug and Fast Track designations for this therapy. While the initial response data showed promising results, Immuneering continues to face financial challenges, reporting a net loss of $14.6 million for the quarter. The company expects additional data from the trial by the end of the year.
Read more →IMRX▲ +42.1%on this news
Preliminary phase 1 safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
The phase 1 study of IMM-1-104, a novel MEK inhibitor, demonstrated good safety and early efficacy in patients with advanced RAS-mutated solid tumors. With 45 subjects enrolled, the study found no serious treatment-related adverse events and promising responses in tumor regression and ctDNA levels. The next phase of the trial is set to explore both mono and combination therapies.
Read more →IMRXImmuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2
Immuneering Corporation reported its second quarter 2024 financial results, highlighting significant progress in its clinical trials, particularly the IMM-1-104 Phase 2a trial for pancreatic cancer, which has received FDA Fast Track designation. The company is on track to deliver initial data from multiple arms of this trial in the second half of 2024. Despite promising developments, financial losses increased to $14.1 million compared to the previous year. The company also anticipates that its current cash reserves will fund operations into the second half of 2025.
Read more →IMRX▼ -5.5%on this news
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - Reported Positive Topline Results from Phase 1 Portion of its Phase 1 2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - -
Immuneering Corporation reported its financial results for Q1 2024, announcing positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104, indicating the treatment's potential for patients with RAS-mutant solid tumors. The company also dosed the first patient in the Phase 2a trial and highlighted promising preclinical data demonstrating synergistic effects when combined with chemotherapy for pancreatic cancer. Despite a net loss increase and rising R&D expenses, the firm expects a data-rich 2024 with initial results anticipated from multiple clinical trial arms.
Read more →IMRXActivity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models
The poster presentation on IMM-1-104 highlights its effectiveness in RAS-altered pancreatic cancer models, showing promising results when combined with chemotherapy agents like gemcitabine and paclitaxel. In preclinical models, IMM-1-104 demonstrated superior tumor growth inhibition compared to standard therapies. The ongoing Phase 2a clinical trial is evaluating its efficacy in patients, with initial data expected in 2024.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1 2a trial of IMM-1-104 expected in March 2024 - - Dosing of first pa
Immuneering Corporation reported its financial results for Q4 and the full year of 2023, highlighting advancements in its clinical trials for drugs IMM-1-104 and IMM-6-415. The company is set to share topline data from the Phase 1 portion of the Phase 1 2a trial of IMM-1-104 in March 2024, with an expanded Phase 2a trial also scheduled to begin dosing its first patient in the same month. Additionally, Immuneering received FDA Fast Track designation for IMM-1-104 in treating pancreatic cancer, underscoring its potential as a significant treatment option.
Read more →IMRX▼ -11.9%on this news
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1 2a trial approximately two-thirds enrolled Immuneering's recommendation for a Phase 2 d
Immuneering Corporation reported its third quarter 2023 financial results, highlighting significant advancements in its clinical trials, particularly the Phase 1 of IMM-1-104. Approximately two-thirds of patients have been enrolled in the trial, with initial data expected in 2024. The company plans to expand to a Phase 2a development plan that includes additional trial arms and anticipates filing an IND for a new candidate, IMM-6-415, in Q4 2023. Financially, Immuneering holds a solid cash position but reported a slight increase in net loss amid rising R&D expenses.
Read more →IMRXDeep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo
The study evaluated the anti-tumor activity of IMM-6-415 in various humanized 3D-TGA models, particularly focusing on BRAF class I-mutant tumors. As a monotherapy, IMM-6-415 exhibited significant anti-tumor effects in over 50% of the models tested. Additionally, it showed superior tumor growth inhibition when combined with encorafenib compared to other treatments, indicating its potential in treating BRAF mutant tumors.
Read more →IMRXPredicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors
IMM-1-104 exhibits promising anti-tumor activity across 20 tumor types, particularly in RAS or RAF mutant tumors. The drug shows high sensitivity in melanoma, pancreatic, and lung cancers. Additionally, it enhances the effectiveness of gemcitabine and paclitaxel in pancreatic cancer models and outperforms binimetinib in combination with encorafenib in terms of tumor growth inhibition.
Read more →IMRXImmuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates - Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) ann
Immuneering Corporation announced its financial results for Q2 2023, highlighting the successful completion of the Phase 1a trial for IMM-1-104, targeting RAS-mutant solid tumors. Positive initial data related to pharmacokinetics and safety were presented at the recent AACR meeting. The company's cash runway has been extended into 2025 following a $30 million financing round, and it anticipates further updates and recommendations for Phase 2 dosing early next year. However, the company is still facing significant net losses and the complexities associated with clinical drug development.
Read more →IMRXBuilding a Universal - RAS Franchise Nasdaq: IMRX APRIL 2023 Investor Presentation 2023 Corporate Presentation 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litiga
IMRX has provided a corporate presentation outlining its development prospects for the Universal - RAS franchise, with a focus on the IMM-1-104 candidate. The company's forward-looking statements highlight the ongoing Phase 1/2a clinical trial set to evaluate its potential effectiveness in targeting a range of RAS mutations. Key milestones include expected initial clinical data and updates on the product pipeline, which aims to provide innovative treatments for cancer. However, the company acknowledges numerous risks that could affect its operational and developmental outcomes.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides
Immuneering Corporation reported its financial results for the fourth quarter and full year 2022, highlighting key advancements in its oncology pipeline. The company announced it dosed the first patient in its Phase 1/2a clinical trial for IMM-1-104, aiming to target advanced solid tumors with any RAS mutation. Looking ahead, it provided timelines for upcoming data readouts and extended its cash runway into Q4 2024, although it also reported a significant increase in net loss compared to the prior year and suspended its neuroscience initiatives.
Read more →IMRXImmuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations ( NCT05585320), with
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares
Read more →IMRXImmuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4
Read more →IMRX▲ +14%on this news
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed to sensitize resistant tumors to select immunotherapies,
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S
Read more →IMRXThe field allows up to 17 characters.
The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNum
Read more →IMRXImmuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, M
Read more →IMRXImmuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expe
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.
Read more →Competitive Position
How IMRX ranks across every disease it competes inCompetitive Position is a premium feature
See how IMRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial